JCI Insight Submission Guide: What to Prepare Before You Submit

JCI Insight states that Research manuscripts report new insights into biology and disease using preclinical models as well as materials and data derived from humans. The same guidance says these manuscripts should be scientifically important and of broad interest to the JCI Insight readership. Clinical Research and Public Health papers, Resource and Technical Advance papers, Research Letters, and Physician-Scientist Development pieces carry different constraints and expectations.

That means the first submission decision is not only category selection. The real decision is whether the manuscript's abstract, first figures, methods, human or disease relevance, and cover letter make the breadth obvious. A disease model alone is not enough. A cohort alone is not enough. A technically strong tool is not enough unless the biological or disease insight is visible.

This guide tells you what JCI Insight editors look for in physician-scientist readership fit; the review tells you whether YOUR paper passes that screen through the abstract, category choice, human evidence, methods, figures, and cover letter before upload. Manusights reviews 1,000+ manuscripts and reports, we do not train models on your manuscript text, and the translational-fit review includes a 60-day money-back guarantee when the deliverable is not met.

In our pre-submission review work with biomedical, translational, preclinical, clinical, cohort, resource, disease-model, immunology, oncology, metabolism, infection, neuroscience, and public-health manuscripts targeting JCI Insight, the recurring issue is not whether the work is real. It is whether the manuscript components make a broad physician-scientist case before the editor loses the thread.

The mechanism is interesting but the disease consequence arrives late

In our pre-submission review work with manuscripts targeting JCI Insight, this pattern appears when the abstract and Figure 1 read like a mechanism paper while the human or disease relevance appears only near the end. JCI Insight can publish preclinical work, but its readership still expects biology and disease relevance to work together. A token cohort, patient sample, clinical table, or final validation panel rarely rescues a manuscript whose real center of gravity is a narrow molecular story.

The manuscript components to test are the abstract, first figure sequence, methods, patient or model description, statistical plan, disease-relevance paragraph, and cover letter. The abstract should name the biological or disease question, not only the pathway. Figure 1 should orient a physician-scientist reader before narrow mechanistic detail takes over. Methods should describe human materials, animal models, cell systems, approvals, statistics, and reproducibility in enough detail for cross-specialty review. The cover letter should explain why JCI Insight is a better target than a specialty biology or disease journal.

Nearby routing matters. If the mechanism is strong but disease relevance is secondary, eLife, The EMBO Journal, Cell Reports, or a specialty mechanistic journal may be cleaner. If the work is clinically important but mechanistically light, a disease-specific clinical journal may fit better. JCI Insight remains credible when mechanism and disease consequence support the same claim.

Check whether your JCI Insight disease relevance is load-bearing →

Human evidence is present but not integrated into the argument

In our pre-submission review work with manuscripts targeting JCI Insight, the second pattern appears when a manuscript contains human samples, patient data, public-health data, clinical metadata, or translational validation, but the human evidence is not doing real argumentative work. Editors and reviewers need to see how the human component changes confidence in the biology, disease mechanism, diagnosis, treatment implication, prevention claim, or public-health interpretation.

The component-level check is specific. The methods should define cohort construction, inclusion and exclusion criteria, approvals, sample handling, assay timing, missing-data handling, statistics, and confounder logic where relevant. Tables should make the study population readable. Figures should connect human evidence to the mechanistic or clinical claim rather than placing it as an isolated validation. The discussion should describe limits honestly, especially when human data are small, retrospective, exploratory, or from a narrow population.

This pattern often means the paper belongs elsewhere for now. A narrow clinical observation may fit a specialty journal. A resource paper may need stronger biological insight before JCI Insight. A public-health analysis may fit a field-specific venue if the physician-scientist readership case is not broad. JCI Insight should remain the target when the human component is central to the paper's importance.

Check whether your JCI Insight human evidence is integrated →

Category choice makes the manuscript look thinner than it is

In our pre-submission review work with manuscripts targeting JCI Insight, the third failure pattern is category mismatch. Authors sometimes force a short high-interest observation into a full Research frame, present a resource without enough biological insight, or treat Clinical Research and Public Health as a home for any human dataset. The result is a submission that feels incoherent even when the underlying study is useful.

The manuscript components to review are the title page, abstract, main text length, figure count, display-item logic, methods, data-availability statement, and cover letter. A Research manuscript should have enough breadth and evidence to justify the full frame. A Research Letter should be sharply focused and built around one display item. A Resource and Technical Advance paper should show why the tool, dataset, or model advances the status quo and yields biological insight. A Clinical Research and Public Health paper should make the human-participant or population contribution central.

If the category is wrong, the editor may read incompleteness where the real problem is packaging. Compare honestly with JCI, Clinical and Translational Medicine, Science Translational Medicine, Nature Communications, The American Journal of Pathology, and specialty clinical journals before uploading. JCI Insight works best when the category and evidence density match.

Check whether your JCI Insight article category matches the manuscript →